Merck’s Dulera Occupies Advantaged Tiers in Many Private Plans Despite Lack of Internal Review by Most MCOs

Sixty-two Percent of Surveyed Pharmacy Directors Expect to Reimburse Boehringer Ingelheim’s Olodaterol/Tiotropium When It Launches in 2013, According to a New Report from HealthLeaders-InterStudy and Fingertip Formulary

NASHVILLE, Tenn. and GLEN ROCK, N.J.--(BUSINESS WIRE)-- HealthLeaders-InterStudy and Fingertip Formulary find that 66 percent of surveyed pharmacy directors reported their managed care organizations (MCOs) had yet to perform an internal review of Merck’s Dulera nine months after its launch for asthma. However, many of these payers had added the long-acting beta2 agonist/inhaled corticosteroid to their formularies. Among MCOs that had not conducted an internal review, 51 percent automatically included Dulera in their dominant private plans, according to a new report entitled Formulary Advantages in Asthma and COPD Therapies.

“Merck has been successful at obtaining favorable tiering for Dulera among the larger plans in part due to its discounted price,” said HealthLeaders-InterStudy product manager Roy Moore, an author of the report.

The report also found that 62 percent of surveyed pharmacy directors expect their MCO to reimburse Boehringer Ingelheim’s olodaterol/tiotropium on either their dominant commercial or Medicare formularies upon its anticipated launch in 2013.

“Olodaterol/tiotropium will compete directly with indacaterol/glycopyrronium when these long-acting beta2 agonist/long-acting muscarinic agonist therapies launch in 2013,” said Moore. “Furthermore, olodaterol/tiotropium will face substantial competition from Boehringer Ingelheim’s Spiriva, which is expected to be less expensive and has strong formulary placement on both commercial and Medicare plans.”

About Fingertip Formulary

Fingertip Formulary (www.FingertipFormulary.com), the leading provider of access to and insight into formulary data in the United States, offers comprehensive formulary data covering commercial, Medicaid, Medicare and PBM plans, among others. Fingertip Formulary is a Decision Resources, Inc. company.

The new Formulary Forum report is based on a survey of 50 U.S. pharmacy directors who control formularies at national, regional and state-level managed care organizations, as well as nationwide formulary data from Fingertip Formulary. To view an abstract of this report please click here.

About HealthLeaders-InterStudy

HealthLeaders-InterStudy, a Decision Resources, Inc. company, is the authoritative source for managed care data, analysis and news. For more information, please visit www.HL-ISY.com.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Both HealthLeaders-InterStudy and Fingertip Formulary are Decision Resources, Inc. companies. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

HealthLeaders-InterStudy
Kristi Guillemette, 781-993-2618
[email protected]
or
Decision Resources Group
Elizabeth Marshall, 781-993-2563
[email protected]

KEYWORDS:   United States  North America  New Jersey  Tennessee

INDUSTRY KEYWORDS:   Health  Clinical Trials  Hospitals  Pharmaceutical  Other Health  Professional Services  Insurance  General Health

MEDIA:

Suggested Articles

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.